90553-43-8

Usage

InChI:InChI=1/C6H8BrNS/c1-8-4-5-2-3-6(7)9-5/h2-3,8H,4H2,1H3/p+1

Upstream product

• 4701-17-1 5-bromo-2-thiophencarboxaldehyde 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 740042-80-2 1-(4-Bromo-phenyl)-2-[(5-bromo-thiophen-2-ylmethyl)-methyl-amino]-ethanol 
• 758642-08-9 2-[(5-Bromo-thiophen-2-ylmethyl)-methyl-amino]-1-p-tolyl-ethanol 
• 765227-25-6 2-[(5-Bromo-thiophen-2-ylmethyl)-methyl-amino]-1-phenyl-ethanol 
• 82230-39-5 2-bromo-4-(4-bromo-phenyl)-6-methyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine 
• 88013-69-8 2-bromo-4-(p-methylphenyl)-6-methyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine 
• 82230-38-4 2-bromo-6-methyl-4-phenyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine 

Relevant academic research and scientific papers

Elimination reactions of N-alkyl-N-chlorothenylamines promoted by MeONa-MeOH and Et2NH-MeCN. Effect of the β-aryl group on the imine-forming transition state

Elimination reactions of N-alkyl-N-chlorothenylamines 1-4 with MeONa-MeOH and Et2NH-MeCN have been studied kinetically. The elimination reactions are regiospecific, producing only the conjugated imines. The reactions are second order and exhibit substantial values of Hammett ρ and k H/kD, and an E2 mechanism is evident. The relative rates of elimination for Me/Et/i-Pr/i-Bu substituents are 1/0.5/0.2/0.02 with MeONa-MeOH and 1/0.4/0.2/0.06 with Et2NH-MeCN. The transition state structure changes toward more product-like as the base is changed from MeONa-MeOH to Et2NH-MeCN. Comparison with existing data reveals that the structure of the transition state is relatively insensitive to the β-aryl group variation.

NOVEL COMPOUNDS THAT MODULATE PPARγ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

The invention relates to novel compounds corresponding to the general formula (I) below: (I) and also to the method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism),-or alternatively in cosmetic compositions.